Reported Earnings • May 26
First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025) First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$643.5k (up 35% from 1Q 2025). Net loss: CA$58.9k (loss narrowed 60% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. New Risk • May 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (CA$9.62m market cap, or US$7.06m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (CA$2.1m revenue, or US$1.5m). Reported Earnings • Apr 08
Full year 2025 earnings released: CA$0.004 loss per share (vs CA$0.03 loss in FY 2024) Full year 2025 results: CA$0.004 loss per share (improved from CA$0.03 loss in FY 2024). Revenue: CA$2.05m (up 146% from FY 2024). Net loss: CA$617.9k (loss narrowed 77% from FY 2024). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Recent Insider Transactions Derivative • Mar 29
CEO & Director exercised options to buy CA$66k worth of stock. On the 23rd of March, Roberto Carducci exercised options to buy 1m shares at a strike price of around CA$0.05, costing a total of CA$60k. This transaction amounted to 17% of their direct individual holding at the time of the trade. Since June 2025, Roberto's direct individual holding has increased from 6.88m shares to 8.08m. Company insiders have collectively bought CA$141k more than they sold, via options and on-market transactions, in the last 12 months. Recent Insider Transactions Derivative • Mar 21
CFO & Corporate Secretary exercised options to buy CA$66k worth of stock. On the 17th of March, Joshua Bald exercised options to buy 1m shares at a strike price of around CA$0.05, costing a total of CA$66k. This transaction amounted to 56% of their direct individual holding at the time of the trade. Since June 2025, Joshua's direct individual holding has increased from 1.66m shares to 2.34m. This was the only transaction from an insider over the last 12 months. Ankündigung • Jan 07
Glow Lifetech Corp. Expands into Medical Cannabis Channel with National Launch on Mendo Glow Lifetech Corp. announced the launch of its MOD™? and .decimal™? product portfolio on the Mendo Medical Cannabis platform ("Mendo"), representing Glow's first formal entry into the Canadian medical cannabis channel and extending access to its products for registered medical patients nationwide. This launch represents an important milestone in Glow's commercial strategy, making its full portfolio (14 SKUs) of next-generation cannabis products available to medical patients across Canada, including veterans, who value greater consistency, dose-control, and personalization. Mendo Medical Cannabis is one of Canada's leading medical cannabis providers, serving registered patients across Canada, with a long-standing focus on veterans through dedicated support programs. Based in Quebec, Mendo operates a national online sales platform, providing both civilians and veterans with easy, secure access to high-quality cannabis products from Canada's top licensed producers. The addition of the medical channel further diversifies Glow's distribution mix heading into 2026 and reinforces the scalability of its business model. Alongside its growing presence with major provincial retailers, this expansion positions the Company to serve a broader customer base while maintaining focus on operational efficiency and long-term value creation. Reported Earnings • Nov 26
Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.005 loss in 3Q 2024) Third quarter 2025 results: CA$0.001 loss per share (improved from CA$0.005 loss in 3Q 2024). Revenue: CA$630.8k (up 178% from 3Q 2024). Net loss: CA$106.0k (loss narrowed 76% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. New Risk • Oct 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.1m free cash flow). Shareholders have been substantially diluted in the past year (41% increase in shares outstanding). Market cap is less than US$10m (CA$8.57m market cap, or US$6.11m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (CA$1.5m revenue, or US$1.0m). Reported Earnings • Aug 28
Second quarter 2025 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 2Q 2024) Second quarter 2025 results: CA$0.002 loss per share. Revenue: CA$436.3k (up 186% from 2Q 2024). Net loss: CA$368.6k (loss widened 42% from 2Q 2024). Ankündigung • Jun 23
Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025 Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025. Ankündigung • Jun 03
Glow Lifetech Corp. Announces the Resignation of James Van Staveren from the Board of Directors Glow Lifetech Corp. announced that Mr. James Van Staveren has resigned from the Board of Directors of the Company, effective May 31, 2025. Reported Earnings • May 07
Full year 2024 earnings released: CA$0.03 loss per share (vs CA$0.029 loss in FY 2023) Full year 2024 results: CA$0.03 loss per share (further deteriorated from CA$0.029 loss in FY 2023). Revenue: CA$836.2k (up CA$792.3k from FY 2023). Net loss: CA$2.66m (loss widened 62% from FY 2023). Over the last 3 years on average, earnings per share has increased by 62% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Ankündigung • Jan 29
Glow Lifetech Corp. Announces Executive and Board Changes Glow LifeTech Corp. announced the appointment of David Ct as a new independent director to the Board of Directors (the "Board"), effective January 24, 2025. Mr. Ct is a seasoned leader in the cannabis retail industry, with extensive experience scaling retail operations and driving growth. David currently serves as Chief Executive Officer of J. Supply Holdings Inc., which owns the cannabis retail banners Northern Helm and J. Supply Co. Prior to this, David was Director of Retail Strategy at Canopy Growth Corporation, where he developed the model for franchising retail cannabis stores across Canada. These endeavours are built on a career in retail, leveraging learnings from the quick-service restaurant, consulting, and CPG industries to the cannabis space, having spent time at RBI, Accenture, and SC Johnson. David earned his MBA and HBA from the Ivey School of Business. The Company also wishes to announced that James Van Staveren has resigned from his position as a member of Glow's Audit Committee and as Corporate Secretary, effective January 24, 2025. Mr. Van Staveren will remain as a director on the Board. Glow would like to sincerely thank Mr. Van Staveren for his valuable services to the Company in his capacity as a member of Glow's Audit Committee and as Corporate Secretary. Effective January 24, 2025, Mr. Ct has been appointed to Glow's Audit Committee and Josh Bald, the Company's Chief Financial Officer, has been appointed as Corporate Secretary. Ankündigung • Nov 06
Glow Lifetech Corp. announced that it expects to receive CAD 0.9 million in funding Glow Lifetech Corp. announced a non-brokered private placement that it will issue up to 18,000,000 units at an issue price of CAD 0.05 per unit for the gross proceeds of up to CAD 900,000 on November 5, 2024. Each Unit issued under the Offering will consist of one Share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of CAD 0.07 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws New Risk • Sep 30
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 113% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (91% average weekly change). Negative equity (-CA$214k). Shareholders have been substantially diluted in the past year (113% increase in shares outstanding). Revenue is less than US$1m (CA$345k revenue, or US$255k). Market cap is less than US$10m (CA$6.68m market cap, or US$4.95m). Ankündigung • Sep 25
Glow Lifetech Corp. announced that it has received CAD 1.2 million in funding On September 24,2024 Glow Lifetech Corp. closed the transaction. In connection with the Offering, the Company paid certain eligible persons: (i) cash commissions in the aggregate of CAD 2,400; and (ii) issued an aggregate of 80,000 finder warrants to such Finders. Each Finder Warrant is exercisable at a price of CAD 0.05 per Common Share until the date that is eighteen (18) months from the date of issuance. The Offering was approved by the members of the board of directors of the Company who are independent for the purposes of the Offering. Ankündigung • Aug 14
Glow Lifetech Corp. announced that it expects to receive CAD 1.2 million in funding Glow Lifetech Corp announced a non-brokered private placement financing of up to 40,000,000 units at a price of CAD 0.03 per Unit for gross proceeds CAD 1,200,000 on August 14, 2024. Each Unit shall be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder thereof to acquire one Common Share at a price of CAD 0.05 per Common Share for a period of eighteen months from the date of issuance. Closing of the Offering is subject to receipt of all necessary corporate and regulatory approvals. All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation. Board Change • Aug 07
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). CEO & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. Independent Director Daniel Proska was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Apr 21
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). ,CEO & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. Independent Director Daniel Proska was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Ankündigung • Apr 17
Glow Lifetech Corp. announced that it expects to receive CAD 0.75 million in funding Glow Lifetech Corp. announced a non-brokered private placement financing of 25,000,000 units at issue price CAD 0.03 per unit for gross proceeds of CAD 750,000 on April 16, 2024. Each unit shall comprise one common share in the capital of the company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of five cents per common share for a period of 18 months from the date of issuance. Closing of the offering is subject to receipt of all necessary corporate and regulatory approvals, including the approval of Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation. New Risk • Feb 18
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (42% average weekly change). Revenue is less than US$1m (CA$19k revenue, or US$14k). Market cap is less than US$10m (CA$1.84m market cap, or US$1.36m). Minor Risk Shareholders have been diluted in the past year (7.4% increase in shares outstanding). Ankündigung • Dec 17
Glow Lifetech Corp. announced that it expects to receive CAD 0.25 million in funding Glow Lifetech Corp. announced a non-brokered private placement of up to 5,000,000 units in the capital of the company at a price of CAD 0.05 per unit for the gross proceeds of up to CAD 250,000 on December 15, 2023. Each unit shall be comprised of one common share in the capital of the company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of CAD 0.07 per common share for a period of 18 months from the date of issuance. The transaction is subject to receipt of all necessary corporate and regulatory approvals. All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation. Ankündigung • Sep 08
Glow Lifetech Corp. Appoints Daniel Proska to Its Board of Directors Glow LifeTech Corp. announce the appointment of Daniel Proska as a new independent director to the Board of Directors, effective, September 6, 2023. With over 15 years of experience in senior sales and revenue growth roles across diverse sectors ranging from medical devices and robotics to software and cybersecurity Mr. Proska has demonstrated a unique capacity for driving business expansion. Notably, his contributions were pivotal in Venus Concepts' growth from $5 million to over $100 million in revenue, and supporting its growth to a NASDAQ listing. Proska's extensive experience in both commercial strategy and operating within regulated environments makes him an invaluable asset to Glow LifeTech. His familiarity with the regulatory complexities in industries such as medical devices and cybersecurity will complement his commercial and strategic acumen, further empowering the Company as it introduces its technology and products to Canada's tightly-regulated emerging cannabis market. Currently, Mr. Proska serves as the Chief Commercial Officer at Scryb Inc., an A.I. Platform that enables businesses across industries to create, enhance, and power disruptive solutions. Among the companies that have benefited from Scryb's capabilities is Cybeats Technologies Corp., a cybersecurity firm where Mr. Proska has contributed to the acquisition of Fortune 500 clients, affirming his capabilities to drive revenue growth and business outcomes. Chris Irwin will step down from his duties as a director of Glow, effective September 6, 2023. Ankündigung • Jul 07
Glow Expands Technology Portfolio and Proprietary Product Format Capabilities; Develops New Water-Soluble Cannabis Powder Technology Glow LifeTech Corp. announce that it has developed a proprietary, water-soluble cannabis powder technology ("New Powder Technology''), which expands the Company's technology portfolio to both liquid and powder cannabinoid ingredients and unlocks a new range of product format capabilities. To protect the New Powder Technology, the Company has submitted provisional patent applications with the United States Patent and Trademark Office. The Company's New Powder Technology creates dry powder cannabinoids that are water-soluble and designed for improved absorption, great taste and a more consistent and predictable cannabis experience. Building on the Company's existing nature-based liquid MyCell® Technology, the New Powder Technology is uniquely made with only natural, plant-based ingredients, and cannabis extracts including THC, CBD, CBN and CBG distillates and isolates. The new powder ingredients expands Glow's growing portfolio of high-performance ingredients, and allows the Company to support a variety of new product formats including capsules, drink mixes, gummies, infused-foods, and more. The Company submitted provisional patent applications to the United States Patent and Trademark Office (USPTO) as part of its ongoing IP strategy for the powder technology. The filings allow Glow to ascribe the phrase "patent pending" to any commercial products, methods, or services contemplated by the subject matter claimed. The patent applications reflect Glow's strategy of strengthening its IP portfolio relating to cannabis and nutraceutical ingredient technologies. MyCell® Technology is Glow's proprietary delivery system that optimizes the absorption, bioavailability and effectiveness of natural active compounds including vitamins, cannabinoids and botanicals, using only 100% natural, food-grade components. It transforms poorly absorbed natural compounds into water-compatible concentrates that have fast-acting onset, high-absorption, precision dosing and a clean taste profile. With its portfolio of ingredients, Glow is powering a new era of more efficient, fast-acting, and great tasting functional foods, beverages, supplements, and personal care products. Ankündigung • Dec 09
Glow Lifetech Corp., Annual General Meeting, Feb 22, 2023 Glow Lifetech Corp., Annual General Meeting, Feb 22, 2023. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Technical Advisory Board Murray Berall was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Nov 03
Glow Lifetech Corp. Completes Development of Proprietary MyCell Liquid Cannabis Ingredients; Advances Plans to Launch in Canadian Market Glow LifeTech Corp. announced the completion of development of its proprietary MyCell® liquid cannabis ingredients, including THC and CBD. The Company now plans for commercialization in the Canadian market, given product readiness. The successful development of MyCell® liquid water-soluble THC and CBD ingredients allows the Company to immediately progress towards scaling-up production and making preparations for sellinginto the well-established market for THC and CBD products in Canada, as the first step in its global commercial strategy. As many cannabis industry players currently struggle with low-margin, commoditized product offerings, Glow has always maintained a long-term focus on delivering differentiated, value-added products and building a platform for high-margin growth. With its portfolio of high-performance, technology-driven products, the Company is well-positioned to capitalize on the growing industry-wide evolution towards high-value, science-based products. Glow's MyCell® Technology is a cutting-edge delivery system that optimizes the absorption, bioavailability and effectiveness of several verticals of natural active compounds including cannabinoids, vitamins, and botanicals, using only 100% natural components. It transforms poorly absorbed natural compounds, such as THC and CBD, into water-soluble compatible concentrates that have fast-acting onset, high-absorption, precision dosing and a clean taste profile. With its flexible technology platform and robust portfolio of enhanced ingredients, Glow can power a variety of product formats including: droppers, sprays, beverages, gummies, foods, topicals, and more. The Company has prudently built an efficient, asset-light cannabis production operation with a factor-in-factory manufacturing partnership in Toronto, Canada, that is designed to scale and minimize costs. With the processing facility built and equipment commissioned in early 2022, it will house all of Glow's cannabis-related R&D activities, serving as the Company's cannabis production centre of excellence to develop technologies and products that can be scaled globally. This single licensed production location provides the Company the necessary production capacity to produce a diverse portfolio of cannabis products to service the Canadian market nationally, across both adult-use and medical cannabis markets. Ankündigung • Jul 19
Glow Lifetech Reports Positive Preliminary Results from Clinical Study of Artemic Support(R) on Patients with Long Covid Syndrome Glow LifeTech Corp. reported positive preliminary results from a clinical study into the influence of ArtemiC Support® on patients with Post-Acute COVID Syndrome, also known as Long COVID. Long COVID refers to the ongoing health problems that people can experience four or more weeks after being infected with SARS-COV-2[2], the virus responsible for COVID-19. Long COVID is believed to affect more than 50% of all COVID-19 patients. The study, undertaken in conjunction with primary care clinicals in Barcelona, CAP Can Bou and Sardenya EAP Spain, was an open label, single arm study, consisting of six-weeks of treatment with ArtemiC Support®. The objectives of the study were to provide an initial assessment of the safety and efficacy of ArtemiC Support® in Long COVID patients. The clinical study was sponsored by Swiss PharmaCan AG and co-sponsored by Glow and MGC Pharmaceuticals Ltd. The study enrolled 150 patients suffering from Long COVID who were administered ArtemiC Support®, under the supervision of their doctor, with their progress being measured using a Post-COVID Functional Scale (PCFS) and symptoms on a 10-point Likert scale at 1, 2, 3 and 6 weeks after treatment initiation. Symptoms measured include: Dyspnea - shortness of breath Asthenia - abnormal physical weakness or lack of energy, Anosmia - loss of senses of smell, Ageusia - loss of sense of taste, Cough, Headache, Mental confusion. The results of the study demonstrated a statistically significant reduction in the severity of several Long COVID symptoms, including Dyspnea, Cough, Asthenia, Headache and Mental Confusion over the course of the protocol. The graphs below show the Emmeans (Estimated Marginal Mean) observed results from data collected during the Artemic Support® Long COVID study: · Dyspnea: a significant difference was seen in reported symptom severity (intensity) (visit 1 to visit 5), with a higher emmean indicating higher severity and a lower enmean indicating a lower severity. · Cough: a significant difference was seen in reported symptom severity (intensity) (visit 1 to visits 4 & 5), with a higher emmeans indicating higher severity and a lower emmeans indicating a lower severity. · Asthenia: a significant difference was seen in reported symptom severity (intensity) (visit 1 to visit 3, 4 and 5), with a higher emmeans indicating higher severity and a lower emmeans indicating a lower severity. Headache: a significant difference was seen in reported symptom severity (intensity) (visit 1 to visit 3, 4 and 5), with a higher emmeans indicating higher severity and a lower enmeans indicating a lower. Mental confusion: a significant difference was seen in reported symptom intensity (visit 1 to visit 5), with a higher emmeans indicating higher severity and a lower emmeans indicating a lower severity. Ankündigung • Jul 09
Glow Lifetech Corp. Provides an Update on Commercial Operations, Cannabis-Related Development Activities and Clinical Studies Related to Its Proprietary Mycell®-Enhanced Products Glow Lifetech Corp. provided an update on commercial operations, cannabis-related development activities and clinical studies related to its proprietary MyCell®-enhanced products. Glow is now focused on the final stages of development of proprietary CBD (cannabidiol) and THC1 (tetrahydrocannabinol) water-soluble ingredients in preparation for launch in Canada. With Glow's licensed cannabis processing space now built out and equipment successfully commissioned earlier this year, the company has been actively developing a diverse portfolio of high-bioavailability cannabis ingredients and new proprietary technologies to expand the Company's portfolio of solutions. The Company's MyCell® Technology is an advanced delivery system that transforms poorly absorbed cannabinoids, like CBD and THC, into water-soluble concentrates that have fast-acting onset, high- absorption and precise dosing. Glow is engaged with a renowned branding firm and is in the late stages of establishing a refreshed brand identity that reflects the cutting-edge performance and quality of its technology and products. The Company is also pleased to report the completion of the recruitment phase of the ongoing clinical study on patients with long COVID syndrome, to assess the impact of its proprietary natural health product Artemic Support®, which features MyCell® Technology.2 Glow's portfolio of high-performance water-soluble cannabis ingredient solutions will unlock a step- change in what's possible with cannabis-infused products, enabling partner brands to easily innovate and differentiate with high-value products that are more effective, fast-acting, consistent and deliver predictable dosing. The versatility of MyCell® enhanced concentrates allows them to power a variety of product formats including: droppers, beverages, foods, topicals, and capsules. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Technical Advisory Board Murray Berall was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • Dec 27
Glow LifeTech Corp Announces Commencement of Clinical Study of Artemic Support Featuring Mycell Technology on Patients with Long COVID Glow LifeTech Corp. announced that it is co-sponsoring a clinical study to assess the impact of its proprietary natural health product Artemic Support®, which features MyCell® Technology, in patients with Long COVID syndrome. Post-acute COVID syndrome (PACS) or "Long COVID" presents itself as a wide range of ongoing symptoms patients can experience for four or more weeks after first being infected with SARS-COV-2[1]. Long Covid is estimated to affect approximately 10%-35% of all COVID patients[2], and the inflammatory response is generally thought to be fundamental to the persistence of symptoms. Therefore, the ability to reduce inflammation could improve patient outcomes, and this study is aimed at validating such a framework for Artemic Support®. Artemic Support® is a natural health product made from curcumin, boswellia and vitamin C designed to reduce inflammatory responses and is formulated with MyCell® Technology ingredients to increase bioavailability and deliver faster, more effective cellular absorption of natural active ingredients. This new innovation is the second product in the Company's Artemic product range to progress to the Clinical Trial phase to determine safety and efficacy against SARS2-COV-2 related diseases. In April 2020, the Company announced it submitted its first product, ArtemicTM Rescue, to Health Canada as a Natural Health Product following successful results from a Phase II Clinical Trial with patients diagnosed with moderate COVID-19. Ankündigung • Apr 29
Glow Lifetech Corp. Submits Application to Health Canada to Obtain Product Licenses for Artemic™ MGC Pharmaceuticals Ltd. announced that Glow LifeTech has submitted an application to Health Canada to obtain product licenses for ArtemiC™ as a Natural Health Product (NHP), per its CSE announcement on 27 April 2021. As announced on 15 December 2020, MGC Pharma released the results of a successful Phase II double-blind, placebo-controlled clinical trial, which showed ArtemiC™ statistically significantly improved the clinical recovery of COVID-19 patients in comparison with the Placebo Group. 100% of the patients in the treatment group met the trial's primary endpoint and fully recovered within 15 days. None of the patients supported by ArtemiC™ required additional oxygen, mechanical ventilation or intensive care, compared to 23.4% in the placebo group requiring further assistance. The results deliver a full safety and efficacy profile, which is further supported by additional testing for toxicity and mechanism of action. ArtemiC™ was submitted to Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD) on March 11, 2021. The application, which is currently under review by Health Canada, included ArtemiC™ supporting COVID-19 Phase II clinical trial results. Under Canadian regulations, all NHPs must obtain premarket approval by Health Canada to assure they are safe, effective and of high quality before being allowed to be sold in Canada. Once Health Canada makes this assessment, they are issued a National Product Number (NPN). Glow has exclusive rights to market, sell and distribute ArtemiC™ in Canada, U.S., Mexico and all Caribbean countries as a food supplement. ArtemiC™ is a clinically tested oral spray containing four natural active ingredients: Artemisinin, Curcumin, Boswellia serrata, and Vitamin C. The formulation uses the MyCell™ delivery system technology to increase bioavailability and effectiveness of natural active ingredients. ArtemiC™ was a collaborative development effort between MGC Pharma, Swiss PharmaCan AG and Glow, and is manufactured by MGC Pharma. 